Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Andy C. Rawstron(University of Leeds), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sue Bell(University of Leeds), Alexander J. Szubert(St James's University Hospital), Walter M. Gregory(University of Leeds), Sylvia Feyler(Calderdale and Huddersfield NHS Foundation Trust), Faith E. Davies(NYU Langone Health), Gordon Cook(University of Leeds), Mark T. Drayson(Institute of Immunology), Nuria Navarro-Coy(University of Leeds), Graham Jackson(Newcastle College), Gareth J. Morgan(Hywel Dda University Health Board), Fiona M. Ross(St James's University Hospital), J. A. Child(Spanish Head & Neck Cancer Cooperative Group), Ruth M. de Tute(St James's University Hospital)
Journal of Clinical Oncology
June 4, 2013
10.1200/jco.2012.46.2119
Cited by 419

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k